Gordana V Krljanac

List of Publications by Year
in descending order

43 papers	798 citations	759233 12 h-index	526287 27 g-index
43 all docs	43 docs citations	43 times ranked	1572 citing authors

#	Article	IF	Citations
1	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	7.1	224
2	Sex Differences in Outcomes After STEMI. JAMA Internal Medicine, 2018, 178, 632.	5.1	183
3	Cognitive functioning and quality of life in patients with Hashimoto thyroiditis on long-term levothyroxine replacement. Endocrine, 2018, 62, 136-143.	2.3	49
4	Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention. Coronary Artery Disease, 2012, 23, 1-8.	0.7	35
5	Effects of Glucose-Insulin-Potassium Infusion on ST-Elevation Myocardial Infarction in Patients Treated With Thrombolytic Therapy. American Journal of Cardiology, 2005, 96, 1053-1058.	1.6	30
6	Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score. International Journal of Cardiology, 2013, 162, 220-227.	1.7	27
7	Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. European Journal of Preventive Cardiology, 2019, 26, 72-82.	1.8	27
8	Type 2 diabetes increases the longâ€term risk of heart failure and mortality in patients with atrial fibrillation. European Journal of Heart Failure, 2020, 22, 113-125.	7.1	23
9	Simple Risk Algorithm to Predict Serious Bleeding in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation Journal, 2013, 77, 1719-1727.	1.6	22
10	Impact of acute hyperglycemia on layer-specific left ventricular strain in asymptomatic diabetic patients: an analysis based on two-dimensional speckle tracking echocardiography. Cardiovascular Diabetology, 2019, 18, 68.	6.8	22
11	Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 56-66.	1.0	19
12	Sex and age differences and outcomes in acute coronary syndromes. International Journal of Cardiology, 2016, 217, S27-S31.	1.7	18
13	Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart and Vessels, 2013, 28, 424-433.	1.2	12
14	Smoking and sex differences in first manifestation of cardiovascular disease. Atherosclerosis, 2021, 330, 43-51.	0.8	12
15	Acute Coronary Syndrome in the COVID-19 Eraâ€"Differences and Dilemmas Compared to the Pre-COVID-19 Era. Journal of Clinical Medicine, 2022, 11, 3024.	2.4	11
16	Gender differences in the prognostic impact of chronic kidney disease in patients with left ventricular systolic dysfunction following ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Hellenic Journal of Cardiology, 2016, 57, 109-115.	1.0	9
17	Coronary Microcirculation in Heart Failure with Preserved Systolic Function. Current Pharmaceutical Design, 2018, 24, 2960-2966.	1.9	8
18	Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial. International Journal of Cardiology, 2013, 167, 1632-1637.	1.7	7

#	Article	IF	Citations
19	Coronary care unit and primary percutaneous coronary intervention networks improve the standard of care: reperfusion therapy in ST elevation myocardial infarction in Serbia from 2002 to 2008. Journal of Cardiovascular Medicine, 2011, 12, 300-302.	1.5	5
20	Using the RISK-PCI Score in the Long-Term Prediction of Major Adverse Cardiovascular Events and Mortality after Primary Percutaneous Coronary Intervention. Journal of Interventional Cardiology, 2019, 2019, 1-9.	1.2	5
21	Crouching tiger, hidden dragon: insulin resistance and the risk of atrial fibrillation. European Journal of Preventive Cardiology, 2020, 27, 1931-1933.	1.8	5
22	In-Hospital and Long-Term Prognosis after Myocardial Infarction in Patients with Prior Coronary Artery Bypass Surgery; 19-Year Experience. Scientific World Journal, The, 2009, 9, 1023-1030.	2.1	4
23	Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. Cardiovascular Drugs and Therapy, 2016, 30, 151-158.	2.6	4
24	Impact on long-term mortality of access and non-access site bleeding after primary percutaneous coronary intervention. Heart, 2019, 105, 1568-1574.	2.9	4
25	Metabolic Syndrome and Myocardial Infarction in Women. Current Pharmaceutical Design, 2021, 27, 3786-3794.	1.9	4
26	Concerns about the use of digoxin in acute coronary syndromes. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 474-482.	3.0	4
27	The Timing of Infarction Pain in Patients with Acute Myocardial Infarction after Previous Revascularization. Scientific World Journal, The, 2008, 8, 598-603.	2.1	3
28	Rationale and Design of the Onâ€Treatment PLAtelet Reactivityâ€Guided Therapy Modification FOR STâ€Segment Elevation Myocardial Infarction (PLATFORM) Randomized Trial. Journal of Interventional Cardiology, 2013, 26, 221-227.	1.2	3
29	Impact of kidney function on the occurrence of new-onset atrial fibrillation in patients with ST-elevation myocardial infarction. , 2021, 25, 638-645.		3
30	Gender Disparities on Access to Care and Coronary Disease Management. Current Pharmaceutical Design, 2021, 27, 3210-3220.	1.9	3
31	Impact of Multivessel Coronary Artery Disease on Long Term Prognosis in Patients with ST-segment Elevation Myocardial Infarction. Journal of Cardiovascular Emergencies, 2019, 5, 66-71.	0.2	3
32	Prognostic impact of renal dysfunction on long-term mortality in patients with preserved, moderately impaired and severely impaired left ventricular systolic function following myocardial infarction. Anatolian Journal of Cardiology, 2018, 20, 21-28.	0.9	3
33	Heart failure with improved ejection fraction: Is a newcomer in the family important?. European Journal of Preventive Cardiology, 2018, 25, 362-365.	1.8	2
34	B-type Natriuretic Peptide and RISK-PCI Score in the Risk Assessment in Patients with STEMI Treated by Primary Percutaneous Coronary Intervention. Clinical Laboratory, 2016, 62, 317-25.	0.5	2
35	Impact of the combined presence of left ventricular systolic and renal dysfunction on the 5-year outcome after ST-elevation myocardial infarction. Vojnosanitetski Pregled, 2015, 72, 702-709.	0.2	1
36	ECHOS survey on echocardiography in Serbia during the COVID-19 pandemic. Srpski Arhiv Za Celokupno Lekarstvo, 2020, 148, 590-593.	0.2	1

#	Article	IF	Citations
37	The use of reperfusion therapy in transition countries without fully applicable pharmacoinvasive strategy. Vojnosanitetski Pregled, 2022, 79, 221-229.	0.2	1
38	Cutting the Gordian knot of left ventricular diastolic dysfunction: Role of opportunistic screening models. European Journal of Preventive Cardiology, 2019, 26, 1666-1669.	1.8	0
39	Glucose-insulin-potassium therapy in acute myocardial infarction: Ten years follow-up. Srce I Krvni Sudovi, 2015, 34, 163-173.	0.1	0
40	Current echocardiography practice in Serbia - a national survey by the Echocardiographic Society of Serbia. Srpski Arhiv Za Celokupno Lekarstvo, 2020, 148, 430-435.	0.2	0
41	Author`s Reply. Anatolian Journal of Cardiology, 2018, 20, 256.	0.9	0
42	The impact of the complete atrioventricular block on in-hospital and long-term mortality in patients treated with primary percutaneous coronary intervention. Vojnosanitetski Pregled, 2023, 80, 16-22.	0.2	0
43	Cardiomyopathies: Classification, diagnosis and treatment modalities. , 2022, 1, 38-48.		0